What are Mission Vision & Core Values of Legend Biotech Company?

How does Legend Biotech define its purpose and values?

Legend Biotech aligns commercial scale-up with breakthrough CAR-T innovation to treat unmet oncology needs. Its strategic statements guide R&D priorities, capital deployment, and global manufacturing expansion.

Mission, vision and core values steer decisions across a workforce of over 1,500, focusing on patient-first innovation, global access, and rigorous scientific integrity.

What are Mission Vision & Core Values of Legend Biotech Company? Core: cure-focused oncology solutions, ethical research practices, collaborative partnerships, and rapid commercialization; see strategic context in Legend Biotech Porter's Five Forces Analysis.

Legend Biotech’s mission focuses on advancing autologous CAR‑T therapies to improve outcomes for patients with refractory or late‑stage malignancies, accelerating access to earlier‑line treatments and expanding into solid tumors.

Patient‑first focus

Prioritizes therapies that extend survival and improve quality of life for patients with limited options.

Innovation in CAR‑T

Develops dual‑epitope VHH‑based CAR‑T platforms to enhance target binding and efficacy.

Clinical advancement

Moved CARVYKTI from fifth‑line to second‑line after CARTITUDE‑4 success, widening patient access.

R&D commitment

Maintains high R&D intensity; 2024–2025 R&D spend remained a significant portion of revenue to pursue solid tumor programs.

Regulatory strategy

Seeks earlier‑line indications to maximize patient benefit and commercial impact.

Ethical standards

Commits to safety, transparency, and access in clinical development and commercialization.

Legend Biotech’s mission aligns patient‑centric innovation, aggressive R&D investment, and regulatory progress to expand CAR‑T impact across hematologic and solid tumors.

Competitors Landscape of Legend Biotech

Vision: To lead global cell therapy innovation, shifting oncology from chronic management to functional cures, with CARVYKTI reaching near $1.8 billion projected net trade sales in FY2025 and expansion into solid tumors and allogeneic platforms.

Global leadership

Targeting worldwide access via dual US-China hubs and extensive manufacturing to support global patient reach.

Therapy transformation

Shifting oncology paradigms from lifelong management to potential functional cures through BCMA and emerging targets.

Commercial traction

CARVYKTI adoption established in multiple jurisdictions, driving strong revenue momentum and market share in BCMA CAR-T.

Pipeline expansion

Advancing DLL3, Claudin 18.2 and allogeneic programs to broaden indications beyond hematologic malignancies.

Operational scale

Investing in manufacturing capacity and supply chains to reduce cost and improve access for cell therapies.

Patient focus

Commitment to patient outcomes guides R&D and commercialization strategies, aligning mission, vision and core values.

To be a global leader in cell therapies, transforming cancer treatment through CAR-T and off-the-shelf platforms, with CARVYKTI projected near $1.8 billion in FY2025 net trade sales and ongoing expansion into solid tumors and new targets; see Brief History of Legend Biotech

Legend Biotech’s core values guide its research, patient care, and commercial operations, aligning scientific rigor with patient-centered outcomes. These values support the company’s mission and vision to advance cell therapies in oncology and rare diseases.

Innovation

Relentless R&D drives proprietary platforms like the VHH approach and iterative manufacturing to minimize T-cell fitness loss, enabling precision tumor targeting and pipeline expansion.

Excellence

Stringent quality and manufacturing standards yielded a production success rate above 95% for CARVYKTI in 2025, reflecting clinical-grade consistency critical for patient safety.

Integrity

Transparent reporting of clinical data and adverse events, including cytokine release syndrome metrics, informs clinicians and regulators and upholds ethical standards.

Collaboration

Strategic partnerships, notably the 50-50 agreement with Janssen Biotech, share costs and profits to scale global regulatory access and commercial infrastructure.

Explore how these values shape strategic decisions and company trajectory next: how mission and vision influence the company's strategic decisions. Read more in this analysis of ownership and governance: Owners & Shareholders of Legend Biotech

Values: Legend Biotech operates under six core values defining its corporate identity and standards; Innovation, Excellence, Integrity, Collaboration, Patient-Focused, Accountability drive platform development, >95% manufacturing success in 2025, transparent clinical reporting, Janssen partnership, patient support programs, and expanded manufacturing sites.

The mission and vision of a biopharma company directly shape its strategic priorities, investment decisions, and operational benchmarks, aligning research, manufacturing, and commercial efforts toward measurable patient impact. Clear corporate purpose guides resource allocation, regulatory engagement, and market entry timing across global programs.

Legend Biotech: Mission, Vision & Core Values

The company’s mission and vision inform R&D choices, manufacturing scale-up and patient-centric commercial models.

• Mission focuses on delivering transformative cell therapies to patients with unmet needs
• Vision targets global leadership in cell therapy for oncology and beyond
• Core values emphasize Integrity, Patient-Focus, Collaboration and Scientific Excellence
• Strategic goals link pipeline expansion with scalable manufacturing and regulatory alignment

Go-to-Market Alignment

Commercial strategy prioritizes rapid access pathways and partnerships to shorten time-to-patient in key markets.

Pipeline Prioritization

Pipeline choices favor programs with high unmet need and clear regulatory pathways to maximize clinical and commercial value.

Manufacturing & Capacity

Investment in a Belgium facility in 2024 expanded EU capacity to support local supply and reduce cryologic shipping delays.

Regulatory & Safety Response

Following FDA inquiries in 2024, the company enhanced safety monitoring and engaged regulators, reflecting Integrity and Patient-Focus.

Patient-Centered Metrics

Success tracked by treatment volumes, patient outcomes and operational metrics like vein-to-vein time reduction.

Leadership Philosophy

CEO statements emphasize curative, 'one-and-done' outcomes as a touchstone for strategic pivots and investment choices.

Influence: The mission and vision drive long-term strategy, exemplified by the 2024 Belgium manufacturing investment and safety protocol upgrades after FDA review; by mid-2025 patients treated rose by 40% year-over-year and vein-to-vein times fell, reflecting alignment with core values and go-to-market goals — read more in Target Market of Legend Biotech

Four focused improvements can sharpen Legend Biotech mission statement and vision to match 2025–2030 industry priorities and market realities. These refinements emphasize affordability, access, therapeutic breadth, and precision to guide R&D, investors, and global patient impact.

Embed affordability and access into the mission

Amend the mission to commit to reducing per-patient costs and improving global access; cell therapies often exceed $450,000 per patient, so a stated affordability goal aligns with value-based care trends.

Highlight expansion into solid tumors

Revise the vision to explicitly include solid tumors and a broader therapeutic horizon, clarifying R&D priorities as the company seeks growth beyond hematologic indications.

Commit to precision and personalization

Emphasize precision oncology and personalized manufacturing in the corporate identity to differentiate from peers and attract precision-medicine investors.

Set measurable, investor-friendly milestones

Introduce time-bound targets (e.g., cost-reduction by 2028, solid-tumor INDs by 2030) to align Legend Biotech strategic goals and values with investor expectations and operational planning.

Improvements

While Legend Biotech's mission and vision are robust, there are areas for strategic refinement to better align with the 2025-2030 industry trajectory. Currently, the mission focuses heavily on 'developing and delivering,' but as the cost of cell therapy remains a significant barrier to global access (with treatments often exceeding $450,000 per patient), the mission could be strengthened by incorporating a commitment to 'accessibility' or 'affordability.' This would align with the industry-wide shift toward value-based healthcare and the emergence of more cost-effective manufacturing technologies.

Another refinement involves explicitly mentioning 'solid tumors' or 'broadening the therapeutic horizon' in the vision statement. While the current vision mentions 'life-threatening diseases,' the company's future growth is heavily dependent on its ability to move beyond hematologic malignancies. A more specific vision that highlights the transition toward treating common solid tumors would provide clearer direction for R&D teams and more specific milestones for investors. Compared to competitors like Bristol Myers Squibb or Gilead, whose missions often emphasize 'transforming patients' lives through science,' Legend could benefit from a more distinct focus on the 'precision' and 'personalization' of its specific technological niche to further differentiate its brand.

See further context on revenue and model considerations in Revenue Streams & Business Model of Legend Biotech